We are seeking a talented and motivated drug discovery scientist who will support small molecule discovery using mass spectrometry. You will develop and implement affinity selection mass spectrometry (ASMS) methods as part of hit validation from our DNA Encoded Library and Virtual Screening platforms to rapidly access chemical matter that modulates targets within the ubiquitin proteome system (UPS). You will use your strong understanding of protein biochemistry to inform the development of assays to assess novel protein-small molecule and protein-protein interactions.
As a member of a dynamic multi-disciplinary project team, you will collaborate with a broad group of scientists within Nurix as well as with external collaborators. You should have a strong desire to learn new techniques and incorporate new methodologies into your work. You must be self-driven, resourceful, organized and focused, and enjoy being a part of a dynamic team in a project-based environment solving challenging scientific problems to benefit patients.
Ph.D. in chemistry, biochemistry, biology or another relevant life science
Expertise in mass spectrometry techniques; relevant training with ASMS is especially desired
Experience with operation, troubleshooting and maintenance of qTOF and sQ mass spectrometers and associated separation techniques (LC, SEC, SPE)
Familiarity with intact mass protein MS, and characterization of protein-small molecule adducts
Experience with the execution of biochemical and/or biophysical assays for evaluation of small molecule modulators
Desire to lead initiatives in platform building and technology development
Solid track record of scientific accomplishment demonstrated by publications, patents, or presentations.
Excellent communication skills and able to present the rationale, key data, issues and accomplishments in a matrix setting
Secondary but desirable qualifications:
Familiarity with spreadsheet management and software such as Spotfire and DotMatics
Understanding of principles and practice of DNA encoded library technology
Expertise in interrogating biochemical mechanism of action, especially for proteins of the UPS
Internal Number: 1
About Nurix Therapeutics
Nurix discovers drugs that harness the body’s natural process to control protein levels. Dysregulated or mutated proteins are at the core of nearly every human disease. Novel therapies that control protein levels provide an opportunity for a new therapeutic approach to alter the development and progression of a broad range of diseases.
Nurix discovers and develops small molecule drugs that control E3 ubiquitin ligases, the key enzymes responsible for protein breakdown in human cells. Our initial focus is on a unique modality that manipulates protein breakdown for new treatments of hematologic cancers, immune-mediated diseases and in applications in immuno-oncology.
In September 2015, Nurix entered into a major collaboration with Celgene for the discovery and development of next-generation therapies targeting E3 ubiquitin ligases in oncology, immunology, and inflammation.
Nurix was founded by a team of experts in E3 ubiquitin ligase regulation and structure. The Nurix management team has extensive experience in biopharmaceutical drug development and is building an innovative biotechnology company around these exciting approaches to create new medicines to improve the li...ves of patients. The company is funded by leading life science investors Third Rock Ventures and The Column Group, and is headquartered in San Francisco’s biotechnology hub, Mission Bay.